Search

Your search keyword '"Nadine Houede"' showing total 5 results
Start Over Author "Nadine Houede" Journal european journal of cancer
5 results on '"Nadine Houede"'

1. 2594 Safety and efficacy of Temsirolimus (Torisel®) as second line treatment for patients with recurrent bladder cancer

Author

Nadine Houede, Florence Joly, Loic Mourey, P. Pourquier, A. Goberna, Lionel Vedrine, B. Lortal, Christian Pfister, Hakim Mahammedi, Stéphane Culine, Guilhem Roubaud, Carine Bellera, and Marina Pulido

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Second line treatment, business.industry, Internal medicine, medicine, Recurrent bladder cancer, business, Temsirolimus, medicine.drug
Published
2015
Full Text
View/download PDF

2. 2627 Characteristics and treatments patterns of patients with an advanced or metastatic urothelial carcinoma (UC) after failure of a platinum-based chemotherapy (CT): Results of the European observational study EPICURE

Author

Franco Morelli, Aline Guillot, R. Tambaro, Nuria Lainez, J.P. Burillon, C. Lucas, Nadine Houede, L. Lusuardi, G. Tonini, X. Garcia del Muro, H. Soto Parra, Umberto Basso, Dominique Spaeth, G.J. Locker, Christine Theodore, and Laura Basterretxea

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, Metastatic Urothelial Carcinoma, business.industry, Internal medicine, medicine.medical_treatment, Medicine, Observational study, business
Published
2015
Full Text
View/download PDF

3. 600 Pharmacokinetics and Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B/AS703026), in Patients with Advanced Solid Tumors

Author

J.H.M. Schellens, Sylvie Rottey, O. von Richter, Nadine Houede, Jean-Pierre Delord, Ahmad Awada, Eric Raymond, Thierry Lesimple, Richard F. Kefford, and Céleste Lebbé

Subjects
Cancer Research, Oncology, Pharmacokinetics, business.industry, Pimasertib, Medicine, In patient, Pharmacology, business
Published
2012
Full Text
View/download PDF

4. 616 Pimasertib (MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows Clinical Activity in Melanoma

Author

Ahmad Awada, Sylvie Rottey, Jan H.M. Schellens, Thierry Lesimple, Eric Raymond, Richard F. Kefford, Nadine Houede, Jean-Pierre Delord, Céleste Lebbé, and N. Rejeb

Subjects
Cancer Research, medicine.medical_specialty, Oncology, business.industry, Family medicine, medicine, Pimasertib, University hospital, business
Abstract

J.P. Delord, N. Houede, A. Awada, C. Lebbe, T. Lesimple, J.H.M. Schellens, S. Rottey, R. Kefford, N. Rejeb, E. Raymond. Centre Claudius Regaud, Clinical Research Unit, Toulouse, France; Institut Bergonie, Bordeaux, France; Jules Bordet Institute, Brussels, Belgium; APHP Hopital Saint-Louis, Paris, France; Centre Eugene Marquis, Rennes, France; The Netherlands Cancer Institute, Amsterdam, The Netherlands; Heymans Institute of Pharmacology Ghent University Hospital, Ghent, Belgium; Westmead Hospital and Melanoma Institute, University of Sydney, Sydney NSW, Australia; Merck Serono S.A. − Geneva, Geneva, Switzerland; Beaujon University Hospital, Clichy, France

Published
2012
Full Text
View/download PDF

5. 7051 POSTER Bicalutamide in Combination With Vandetanib or Placebo in Patients With Castration-refractory Metastatic Prostate Cancer Without Any Clinical Symptom Related to Disease Progression – a Randomized, Double-blind Phase II Trial

Author

J.-C. Eymard, K. Fizazi, Christophe Hennequin, A. Tisseron Carrasco, Stéphane Oudard, S. Le Moulec, P. Beuzeboc, Nadine Houede, Stéphane Culine, and Y. Loriot

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Bicalutamide, business.industry, Disease progression, Vandetanib, Placebo, medicine.disease, Double blind, chemistry.chemical_compound, Prostate cancer, Castration, Refractory, chemistry, Internal medicine, medicine, business, medicine.drug
Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results